Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United Kingdom
  4. London Stock Exchange
  5. HUTCHMED (China) Limited
  6. News
  7. Summary
    HCM   KYG4672N1198

HUTCHMED (CHINA) LIMITED

(HCM)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Hutchmed to Present Cancer Drug Clinical Data at US Hematology Conference

11/08/2021 | 06:07am EST


© MT Newswires 2021
All news about HUTCHMED (CHINA) LIMITED
01/20Hutchison China MediTech Doses First Patient in Phase 1 Study to Treat Advanced Solid T..
MT
01/20HUTCHMED CHINA : Initiates a Phase I Trial of HMPL-653 in Patients with Advanced Malignant..
PU
01/20Hutchmed Commences Phase I Trial of Tumor Drug Candidate HMPL-653 in China
MT
01/20Hutchmed Launches Early-Stage Trial Of Cancerous Tumor Treatment In China
MT
01/20HUTCHMED Limited Initiates a Phase I Trial of HMPL-653 in Patients with Advanced Malign..
CI
01/19Hutchmed Starts Cancer Drug's Phase I Study in China
MT
01/19HUTCHMED Initiates a Phase I Trial of HMPL-653 in Patients with Advanced Malignant Soli..
AQ
01/19HUTCHMED CHINA : Highlights Fruquintinib Clinical Data to be Presented at the 2022 ASCO Ga..
PU
01/19HUTCHMED Limited Update Analysis of Ongoing International Phase I/Ib Trial of Fruquinti..
CI
01/18Hutchmed China to Present Data From Clinical Trial of Colorectal Cancer Treatment at On..
MT
More news
Analyst Recommendations on HUTCHMED (CHINA) LIMITED
More recommendations
Financials (USD)
Sales 2021 339 M - -
Net income 2021 -262 M - -
Net cash 2021 1 212 M - -
P/E ratio 2021 -19,5x
Yield 2021 -
Capitalization 5 119 M 5 121 M -
EV / Sales 2021 11,5x
EV / Sales 2022 9,06x
Nbr of Employees 1 280
Free-Float 51,3%
Chart HUTCHMED (CHINA) LIMITED
Duration : Period :
HUTCHMED (China) Limited Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends HUTCHMED (CHINA) LIMITED
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 4
Last Close Price 5,98 $
Average target price 9,31 $
Spread / Average Target 55,8%
EPS Revisions
Managers and Directors
Christian Hogg Chief Executive Officer & Executive Director
Chig Fung Cheng Chief Financial Officer
Chi Keung To Executive Director
Wei Guo Su Executive Director & Chief Scientific Officer
Marek Kania Chief Medical Officer & Managing Director
Sector and Competitors
1st jan.Capi. (M$)
HUTCHMED (CHINA) LIMITED-16.79%5 121
JOHNSON & JOHNSON-3.40%434 036
ROCHE HOLDING AG-4.87%319 830
PFIZER, INC.-10.60%296 303
ABBVIE INC.-2.53%233 325
ELI LILLY AND COMPANY-11.98%220 356